Neuroradiology

In Vivo 3-T MR Spectroscopy in the Distinction of Recurrent Glioma versus Radiation Effects: Initial Experience

Abstract

PURPOSE: To determine if 3-T magnetic resonance (MR) spectroscopy allows accurate distinction of recurrent tumor from radiation effects in patients with gliomas of grade II or higher.

MATERIALS AND METHODS: This blinded prospective study included 14 patients who underwent in vivo 3-T MR spectroscopy prior to stereotactic biopsy. All patients received a previous diagnosis of glioma (grade II or higher) and high-dose radiation therapy (>54 Gy). Prior to MR spectroscopy, conventional MR imaging was performed at 1.5 T to identify a gadolinium-enhanced region within the irradiated volume. Diagnosis was assigned by means of histopathologic analysis of the biopsy samples.

RESULTS: Sixteen of 17 biopsy locations could be classified as predominantly tumor or predominantly radiation effect on the basis of the ratio of choline at the biopsy site to normal creatine level by using a value greater than 1.3 as the criterion for tumor. The remaining case, classified as recurrent tumor on the basis of MR spectroscopy results, was diagnosed as predominantly radiation effect on the basis of histopathologic findings. Disease in this patient progressed to biopsy-proven recurrence within 3 months. Overall, the ratio of choline at the biopsy site to normal creatine level was significantly elevated (unpaired two-tailed Student t test, P < .002) in those biopsy samples composed predominantly of tumor (n = 9) compared with those containing predominantly radiation effects (n = 8). The ratio was not significantly different between the two histopathologic groups.

CONCLUSION: In vivo 3-T MR spectroscopy has sufficient spatial resolution and chemical specificity to allow distinction of recurrent tumor from radiation effects in patients with treated gliomas.

References

1 Tatter S, Wilson C, Harsh GI. Neuroepithelial tumors of the adult brain. In: Youmans J, eds. Neurological surgery. Philadelphia, Pa: Saunders, 1996; 2612-2684. Google Scholar
2 Karim A. Radiation therapy and radiosurgery for brain tumors. In: Kaye A, Laws EJ, eds. Brain tumors: an encyclopedic approach. Edinburgh, Scotland: Churchill Livingstone, 1995; 331-348. Google Scholar
3 Harsh GI. Management of recurrent gliomas and meningiomas. In: Kaye A, Laws EJ, eds. Brain tumors: an encyclopedic approach. Edinburgh, Scotland: Churchill Livingstone, 1995; 413-428. Google Scholar
4 Black P, Wen P. Clinical imaging and laboratory diagnosis of brain tumors. In: Kaye A, Laws EJ, eds. Brain tumors: an encyclopedic approach. Edinburgh, Scotland: Churchill Livingstone, 1995; 191-214. Google Scholar
5 Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35:606-614. Crossref, Medline, Google Scholar
6 Kuesel AC, Sutherland GR, Halliday W, Smith I. 1H MR spectroscopy of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994; 7:149-155. Crossref, Medline, Google Scholar
7 Peeling J, Sutherland G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn Reson Med 1992; 24:123-136. Crossref, Medline, Google Scholar
8 Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neuroscience 1993; 13:981-989. Crossref, Medline, Google Scholar
9 Castillo M, Kwock L. Proton MR spectroscopy of common brain tumors. Neuroimaging Clin N Am 1998; 8:733-752. Medline, Google Scholar
10 Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185:675-686. Link, Google Scholar
11 Hagberg G, Burlina A, Mader I, Roser W, Radue E, Seelig J. In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification. Magn Reson Med 1995; 34:242-252. Crossref, Medline, Google Scholar
12 Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996; 84:449-458. Crossref, Medline, Google Scholar
13 Vaughan J, Hetherington H, Harrison J, et al. High frequency coils for clinical nuclear magnetic resonance imaging and spectroscopy. Phys Med 1993; 9:147-153. Google Scholar
14 Reese T, Davis T, Weisskoff R. Automated shimming at 1.5 T using echo planar image frequency maps. J Magn Reson Imaging 1995; 5:739-745. Crossref, Medline, Google Scholar
15 Hetherington HP, Mason GF, Pan JW, et al. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med 1994; 32:565-571. Crossref, Medline, Google Scholar
16 Mlynarik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 2001; 14:325-331. Crossref, Medline, Google Scholar
17 Henriksen O. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed 1995; 8:139-148. Crossref, Medline, Google Scholar
18 Chan YL, Yeung DK, Leung SF, Cao G. Proton magnetic resonance spectroscopy of late delayed radiation-induced injury of the brain. J Magn Reson Imaging 1999; 10:130-137. Crossref, Medline, Google Scholar
19 Chong VF, Rumpel H, Aw YS, Ho GL, Fan YF, Chua EJ. Temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma: 1H MR spectroscopic findings. Int J Radiat Oncol Biol Phys 1999; 45:699-705. Crossref, Medline, Google Scholar
20 Segebarth C, Baleriaux D, Luyten P, den Hollander J. Detection of metabolic heterogeneity of human intracranial tumors by in vivo 1H NMR spectroscopic imaging. Magn Reson Med 1990; 13:62-76. Crossref, Medline, Google Scholar
21 Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996; 17:737-747. Medline, Google Scholar
22 Sijens PE, Knopp MV, Bunetti A, et al. 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med 1995; 33:818-826. Crossref, Medline, Google Scholar
23 Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2:323-325. Crossref, Medline, Google Scholar
24 Kugel H, Heindel W, Ernestus RI, Bunke J, du Mesnil R, Friedman G. Human brain tumors: spectral patterns detected with localized H-1 spectroscopy. Radiology 1992; 183:701-709. Link, Google Scholar
25 Preul MC, Leblanc R, Caramanos Z, Kasrai R, Narayanan S, Arnold DL. Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 1998; 25:13-22. Crossref, Medline, Google Scholar
26 Heesters M, Kamman RL, Mooyaart EL. Localized proton spectroscopy of inoperable brain gliomas: response to radiation therapy. J Neurooncol 1993; 17:27-35. Crossref, Medline, Google Scholar
27 Sijens P, Vecht C, Levendag P, van Dijk P, Oudkerk M. Hydrogen magnetic resonance spectroscopy follow-up after radiation therapy of human brain cancer. Invest Radiol 1995; 30:738-744. Crossref, Medline, Google Scholar
28 Wald L, Moyher S, Day M, Nelson S, Vigneron D. Proton spectroscopic imaging of the human brain using phased array detectors. Magn Reson Med 1995; 34:440-445. Crossref, Medline, Google Scholar
29 Ikehira H, Miyamoto T, Yasukawa T, et al. Differences in metabolic and morphological reactions after radiation therapy: proton NMR spectroscopy and imaging of patients with intracranial tumors. Radiat Med 1995; 13:199-204. Medline, Google Scholar
30 Usenius T, Usenius J, Tenhunen M, et al. Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1995; 33:719-724. Crossref, Medline, Google Scholar
31 Walecki J, Sokol M, Pieniazek P, et al. Role of short TE 1H-MR spectroscopy in monitoring of postoperation irradiated patients. Eur J Radiol 1999; 30:154-161. Crossref, Medline, Google Scholar
32 Taylor JS, Langston JW, Reddick WE, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996; 36:1251-1261. Crossref, Medline, Google Scholar
33 Bovee WM, Karlsen OT, Rozijn TH. Spatial resolution and spectral information content of proton NMR spectroscopic imaging of tumour metabolism. Anticancer Res 1996; 16:1515-1520. Medline, Google Scholar
34 Ott D, Henning J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993; 186:745-752. Link, Google Scholar
35 Rand SD, Prost R, Li SJ. Proton MR spectroscopy of the brain. Neuroimaging Clin N Am 1999; 9:379-395. Medline, Google Scholar
36 Nelson SJ. Imaging of brain tumors after therapy. Neuroimaging Clin N Am 1999; 9:801-819. Medline, Google Scholar
37 Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87:516-524. Crossref, Medline, Google Scholar
38 Barker PB, Soher BJ, Blackband SJ, Chatham JC, Mathews VP, Bryan RN. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR Biomed 1993; 6:89-94. Crossref, Medline, Google Scholar
39 Barker PB, Breiter SN, Soher BJ, et al. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 1994; 32:157-163. Crossref, Medline, Google Scholar
40 Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997; 87:525-534. Crossref, Medline, Google Scholar

Article History

Published in print: Dec 2002

Vol. 225, No. 3

Metrics

Downloaded 347 times

Altmetric Score